Company profile / IVA

Inventiva

Clinaptis stanceNeutral
Ticker
IVA
Exchange
Euronext Paris and Nasdaq
Coverage
Standard profile
Updated
Nov 12, 2026
Hepatology / MASH

Clinical-stage biopharma company. Lanifibranor, an oral pan-PPAR agonist, is in the Phase 3 NATiV3 trial in MASH (metabolic dysfunction-associated steatohepatitis). After the 2025 decision to stop all other research, it is the asset on which almost the whole company now depends. Shares trade on Euronext Paris and, as ADS, on Nasdaq. Market value about €0.80B at the 10 November 2026 Euronext close of €3.36 (about $0.94B at the $3.95 ADS close that day).

01 / Clinaptis view

The current read

Neutral, with the skew to the upside. NATiV3 can meet its primary endpoint and still leave Inventiva worth €2.62 a share against a €3.36 price, if the win is narrow: a composite gain under 10 points or a weak fibrosis result.

  1. We put a primary hit at 78%. On our branch values the price breaks even at 63% to 77%, depending on what a persuasive win is worth.
02 / Consensus gap

Where the market may differ

A hit is not enough; the stock needs a persuasive result. Break-even needs the persuasive branch worth about €0.95B of enterprise value, roughly where Inventiva trades today, against the €1.6B we assume.

  1. The financing sharpens the tails: a secondary-only result can make the warrants exercisable while putting the debt in default.
Coverage state
Standard profile
What the review turns on
Key variable

How large the composite and fibrosis gains are at 1,200 mg. A primary hit is likely (78% in our model), but a narrow win is worth less than the price; the fibrosis gain, not the p-value, decides which side the result lands.

Next catalyst

Lanifibranor · NATiV3 Phase 3 topline in MASH · Q4 2026 (company guidance)

03 / Pipeline

Key programs

1 asset · 1 program

AssetIndicationStageNext event
Lanifibranor
MASH with F2–F3 fibrosis
Phase 3
Topline in Q4 2026 (company guidance); management said on Nov 9 that data should arrive within about eight weeks. We model a 12-point composite gain at 1,200 mg and a primary hit in about 78% of simulated trials
04 / Connected research

Published on IVA

View full archive
  1. 01

    Even a MASH Win May Not Be Enough for Inventiva

    Inventiva trades at €3.36 weeks before NATiV3, a 72-week Phase 3 that tests lanifibranor on the strictest histology endpoint in MASH. If the trial hits, how large do the composite and fibrosis gains need to be for the shares to be worth more than the price, and what does the financing do to the equity if it misses?

    Read